ORLANDO, Fla., April 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced ...

ORLANDO, FL / ACCESSWIRE / March 25, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that ...

ORLANDO, FL / ACCESSWIRE / March 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that ...

Patent issuance expands United States patent coverage for AVERSA™ transdermal abuse deterrent technology AVERSA™ transdermal abuse deterrent technology is protected by a broad international ...

Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe ...

Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology ...

Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function. The Clinical Kidney Journal in February ...

Nutriband is developing its proprietary Aversa® abuse-deterrent transdermal technology which can be incorporated into any transdermal patch that contains any drug with a risk of abuse, misuse or ...

(MENAFN- GlobeNewsWire - Nasdaq) Nutriband's abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband is targeting to file for FDA ...